Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

Journal of Medicinal Chemistry

Volumn 42, Issue 12, 1999, Pages 2180-2190

  Liverton, Nigel J ^a   Butcher, John W ^a   Claiborne, Christopher F ^a   Claremon, David A ^a   Libby, Brian E ^a   Nguyen, Kevin T ^a   Pitzenberger, Steven M ^a   Selnick, Harold G ^a   Smith, Garry R ^a   Tebben, Andrew ^a   Vacca, Joseph P ^a   Varga, Sandor L ^a   Agarwal, Lily ^a   Dancheck, Kim ^a   Forsyth, Amy J ^a   Fletcher, Daniel S ^a   Frantz, Betsy ^a   Hanlon, William A ^a   Harper, Coral F ^a   Hofsess, Scott J ^a   Kostura, Matthew ^a   Lin, Jiunn ^a   Luell, Sylvie ^a   O'Neill, Edward A ^a   Orevillo, Chad J ^a   Pang, Margaret ^a   Parsons, Janey ^a   Rolando, Anna ^a   Sahly, Yousif ^a   Visco, Denise M ^a   O'Keefe, Stephen J ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 AMINOPYRIMIDINYL) 4 [3 (TRIFLUOROMETHYL)PHENYL] 2 (4 PIPERIDYNYL)IMIDAZOLE; 5 [2 (1 PHENYLETHYLAMINO)PYRIDIN 4 YL] 1 METHYL 4 [3 (TRIFLUOROMETHYL)PHENYL] 2 (4 PIPERIDINYL)IMIDAZOLE; 5 [2 (1 PHENYLETHYLAMINO)PYRIMIDIN 4 YL] 1 METHYL 4 [3 TRIFLUOROMETHYL)PHENYL 2 (4 PIPERIDINYL)IMIDAZOLE; 5 [2 (1 PHENYLETHYLAMINO)PYRIMIDIN 4 YL] 4 [3 TRIFLUOROMETHYL)PHENYL] 2 (4 PIPERIDINYL)IMIDAZOLE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; METHYLATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; AMINOPYRIDINES; ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL AVAILABILITY; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; MACACA MULATTA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; STIMULATION, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033578080     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9805236     Document Type: Article

References (32)

1. Koj, A. Initiation of Acute Phase Response and Synthesis of Cytokines Biochim. Biophys. Acta 1996, 1317, 84-94.
2. Dinarello, C. A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases Curr. Opin. Immunol. 1991, 3, 941-948.
3. Tracey, K. J.; Cerami, A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 1993, 9, 317-343.
4. Elliott, M. J.; Maini, N. M.; Feldmann, M.; Kalden, J. R.; Antoni, C.; Smolen, J. S.; Leeb, B.; Breedveld, F. C.; Macfarlane, J. D.; Bijl, H.; Woody, J. N. Randomized double blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344, 1105-1110.
5. Elliott, M. J.; Maini, N. M.; Feldmann, M.; Long-Fox, A.; Charles, P.; Bijl, H.; Woody, J. N. Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344, 1125-1127.
6. Rankin, E. C. C.; Choy, E. H. S.; Kassimos, D.; Kingsley, G. H.; Sopwith, A. M.; Isenberg, D. A.; Panayi, G. S. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 1996, 34, 334-342.
7. Van Dullemen, H. M.; Van Deventer, S. J. H.; Hommes, D. W.; Bijl, H.; Jansen, J.; Tytgat, G. N. J.; Woody, J. N. Treatment of Crohn's Disease with Antitumor Necrosis Factor Chimeric Monoclonal Antibody (cA2). Gastroenterology 1995, 109, 129-135.
8. Moreland, L. W.; Baumgartner, S. W.; Schiff, M. H.; Tindall, E. A.; Fleischmann, R. M.; Weaver, A. L.; Ettlinger, R. E.; Cohen, S.; Koopman, W. J.; Mohler, K.; Widmer, M. B.; Blosch, C. M. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein. N. Engl. J. Med. 1997, 337, 141-147.
9. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kimar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-745.
10. Paul, A.; Wilson, S.; Belham, C. M.; Robinson, C. J. M.; Scott, P. H.; Gould, G. W.; Plevin, R. Stress Activated Protein Kinases: Activation, Regulation and Function Cell Signal 1997, 9, 403-410.
11. Han, J.; Lee, J.-D.; Jiang, Y.; Li, Z.; Feng, L.; Ulevitch, R. J. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 1996, 271, 2886-2891.
12. Raingeaud, J.; Gupta, S.; Rogers J. S.; Dickens, M.; Han, J.; Ulevitch, R. J.; Davis, R. J. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 1995, 270, 7420-7426.
13. Cuenda, A.; Rouse, J.; Doza, Y. N.; Meier, R.; Cohen, P.; Gallagher, T. F.; Young, P. R.; Lee J. C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995, 364, 229-233.
14. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacologic profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 1996, 279, 453-461.
15. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of Stress-Induced Cytokine Production by Pyridnylimidazoles; Inhibition of CSBP Kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
16. Friz, L. P. Nitrogen-substituted derivatives of 1-(4-pyridyl)-2-amino-ethanol. Farmaco Ed. Sci. 1963, 18, 972.
17. Choshi, T.; Yamada, S.; Sugino, E.; Kuwada, T.; Hibino, S. The Total Synthesis of the Marine Antitumor Grossularine-2. Synlett 1995, 147-148.
18. Majeed, A. J.; Antonsen, O.; Benneche, T.; Undheim, K. Stannylation Reactions and Cross-Couplings in Pyrimidmes. Tetrahedron 1989, 45, 993-1006.
19. Strekowski, L.; Wydra, R. L.; Janda, L.; Harden, D. B. Highly Regioselective Bromination Reactions of Polymethylpyrimidines. J. Org. Chem. 1991, 56, 5610-5614.
20. Freeman, J. P.; Gannon, J. J.; Surbey, D. L. The Nitrosation of a,b-Unsaturated Oximes IV The Synthesis and Structure of 3,4-Diazacyclopentadienone Derivatives. J. Org. Chem. 1969, 34, 187-194.
21. Maligres, P. E.; Houpis, I.; Rossen, K.; Molina, A.; Sager, J.; Upadhyay, V.; Wells, K. M.; Reamer, R A.; Lynch, J. E.; Askin, D.; Volante, R. P.; Reider, P. J.; Houghton, P. Synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677. Tetrahedron 1997, 53, 10983-10992.
22. Jung, F.; Delvare, C.; Boucherot, D.; Hamon, A. Cephalosporins with C-7-isocyanide dihalides: Useful synthons for the introduction of amino heterocycles at C-7 - new routes to the synthesis of amino imidazoles. Tetrahedron Lett. 1989, 30, 2375-2378.
23. Hayes, K. 1-Hydroxyimidazole 3-Oxide and Some 2-Substituted Derivatives. J. Heterocycl. Chem. 1974, 11, 615-618.
24. Lipshutz, B. H.; Morey, M. C. Ti(III)-Mediated reductions of N-hydroxy imidazoles to 1-protio-2,4(5)-disubstituted imidazoles. Tetrahedron Lett. 1984, 25, 1319-1320.
25. SanMartin, R.; Olivera, R.; deMarigorta, E. M.; Dominguez, E. A New General Method for the Synthesis of 4-Hydroxylated 3-Aryltetrahydroisoquinolines. Tetrahedron 1995, 51, 5361-5368.
26. Fletcher, D. S.; Widmer, W. R.; Luell, S.; Christen, A.; Orevillo, C.; Shah, S.; Visco, D. Therapeutic Administration of a Selective Inhibitor of Nitric Oxide Synthase Does Not Ameliorate the Chronic Inflammation and Tissue Damage Associated with Adjuvant-Induced Arthritis in Rats. J. Pharmacol. Exp. Ther. 1998, 284, 714-721.
27. El Hadri, A.; Leclerc, G. A Convenient Synthesis of cis-4-(Sulfomethyl)piperidine-2-carboxylic acid: NMR Assignment. J. Heterocycl. Chem. 1997, 30, 631-635.
28. Selnick, H. G.; Claremon, D. A.; Liverton, N. J. Substituted imidazoles having anti-cancer and cytokine inhibitory activity. World Patent Application 9712876.
29. Kawaski, I.; Yamashita, M.; Ohta, S. Total Synthesis of Nortopsentins A-D, marine alkaloids. Chem. Pharm. Bull. 1996, 44, 1831-1839.
30. Chen, I.-W.; Lin, J. Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals. Drug Metab. Dispos. 1994, 22, 693-699.
31. Chiba, C.; Nishime, J. A.; Lin, J. H. Potent and selective inactivation of human liver microsomal cytochrome P-450 Isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J. Pharmacol. Exp. Ther. 1995, 275, 1527-1533.
32. LoGrasso, P. V.; Frantz, B.; Rolando, A. M.; O'Keefe, S. J.; Hermes, J. D.; O'Neill, E. A. Kinetic Mechanism For P38 Map Kinase. Biochemistry 1997, 36, 10422-10427.